Cue Biopharma Management
Management criteria checks 2/4
Cue Biopharma's CEO is Dan Passeri, appointed in Aug 2016, has a tenure of 7.75 years. total yearly compensation is $3.02M, comprised of 20.1% salary and 79.9% bonuses, including company stock and options. directly owns 0.28% of the company’s shares, worth $286.65K. The average tenure of the management team and the board of directors is 6 years and 5.9 years respectively.
Key information
Dan Passeri
Chief executive officer
US$3.0m
Total compensation
| CEO salary percentage | 20.1% |
| CEO tenure | 7.8yrs |
| CEO ownership | 0.3% |
| Management average tenure | 6yrs |
| Board average tenure | 5.9yrs |
Recent management updates
Recent updates
Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money
Apr 16
Does Cue Biopharma (NASDAQ:CUE) Have A Healthy Balance Sheet?
Dec 30Is Cue Biopharma (NASDAQ:CUE) Using Too Much Debt?
Aug 11Cue Biopharma shares rise ~10% on FDA fast track nod for head and neck cancer drug
Oct 04Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt
Sep 23News Flash: 4 Analysts Think Cue Biopharma, Inc. (NASDAQ:CUE) Earnings Are Under Threat
Aug 26Analysts Just Shipped A Huge Upgrade To Their Cue Biopharma, Inc. (NASDAQ:CUE) Estimates
Aug 10Analysts Have Just Cut Their Cue Biopharma, Inc. (NASDAQ:CUE) Revenue Estimates By 23%
May 18Cue Biopharma (NASDAQ:CUE) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
May 12Cue Biopharma: A First Assessment
May 11Earnings Beat: Cue Biopharma, Inc. (NASDAQ:CUE) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Mar 19Cue Biopharma: Too Long To Arrive At Topline Trial Data
Feb 23We Think Cue Biopharma (NASDAQ:CUE) Can Afford To Drive Business Growth
Nov 04Cue Biopharma doses first patient in trial for CUE-101 in head and neck cancer
Jun 10Companies Like Cue Biopharma (NASDAQ:CUE) Are In A Position To Invest In Growth
Jun 07Cue Biopharma's CUE-101 shows encouraging action in HPV+ head and neck cancer patients
May 10How Many Cue Biopharma, Inc. (NASDAQ:CUE) Shares Did Insiders Buy, In The Last Year?
Mar 21We're Not Very Worried About Cue Biopharma's (NASDAQ:CUE) Cash Burn Rate
Feb 22Is Cue Biopharma, Inc. (NASDAQ:CUE) Popular Amongst Insiders?
Jan 27
Cue Biopharma: CUE-101's Phase 1 Promising Progress, 1 New IND Expected, Funding Until Q2 2022
Jan 07Reflecting on Cue Biopharma's (NASDAQ:CUE) Share Price Returns Over The Last Year
Dec 25Independent Director Aaron Fletcher Just Bought 3.9% More Shares In Cue Biopharma, Inc. (NASDAQ:CUE)
Nov 29We're Not Very Worried About Cue Biopharma's (NASDAQ:CUE) Cash Burn Rate
Nov 24Cue Biopharma (CUE) Investor Presentation - Slideshow
Nov 20Cue Biopharma EPS beats by $0.12, misses on revenue
Nov 17CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$3m | US$605k | -US$51m |
| Sep 30 2023 | n/a | n/a | -US$52m |
| Jun 30 2023 | n/a | n/a | -US$52m |
| Mar 31 2023 | n/a | n/a | -US$52m |
| Dec 31 2022 | US$1m | US$748k | -US$53m |
| Sep 30 2022 | n/a | n/a | -US$47m |
| Jun 30 2022 | n/a | n/a | -US$49m |
| Mar 31 2022 | n/a | n/a | -US$46m |
| Dec 31 2021 | US$2m | US$531k | -US$44m |
| Sep 30 2021 | n/a | n/a | -US$47m |
| Jun 30 2021 | n/a | n/a | -US$44m |
| Mar 31 2021 | n/a | n/a | -US$44m |
| Dec 31 2020 | US$6m | US$501k | -US$45m |
| Sep 30 2020 | n/a | n/a | -US$43m |
| Jun 30 2020 | n/a | n/a | -US$40m |
| Mar 31 2020 | n/a | n/a | -US$38m |
| Dec 31 2019 | US$1m | US$395k | -US$37m |
| Sep 30 2019 | n/a | n/a | -US$39m |
| Jun 30 2019 | n/a | n/a | -US$45m |
| Mar 31 2019 | n/a | n/a | -US$43m |
| Dec 31 2018 | US$834k | US$345k | -US$39m |
| Sep 30 2018 | n/a | n/a | -US$38m |
| Jun 30 2018 | n/a | n/a | -US$30m |
| Mar 31 2018 | n/a | n/a | -US$27m |
| Dec 31 2017 | US$410k | US$325k | -US$23m |
Compensation vs Market: Dan's total compensation ($USD3.02M) is above average for companies of similar size in the US market ($USD663.90K).
Compensation vs Earnings: Dan's compensation has increased whilst the company is unprofitable.
CEO
Dan Passeri (62 yo)
7.8yrs
Tenure
US$3,015,480
Compensation
Mr. Daniel R. Passeri, also known as Dan, MSc. J.D. has been the Chief Executive Officer and Director of Cue Biopharma, Inc. since August 2016 and also served as its President since August 2016 until Octob...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 7.8yrs | US$3.02m | 0.28% $ 286.6k | |
| President & Chief Scientific Officer | 6yrs | US$1.21m | 0.28% $ 288.9k | |
| Chief Financial Officer | 6yrs | US$1.16m | 0.029% $ 30.5k | |
| Co-Founder | no data | US$316.63k | no data | |
| Co-Founder & Senior Advisor | no data | US$316.63k | no data | |
| Co-Founder and Chairman of Scientific & Clinical Advisory Board | no data | no data | no data | |
| Senior VP | 6.4yrs | US$625.51k | no data | |
| Chief Medical Officer | 3.3yrs | no data | 0.019% $ 19.7k |
6.0yrs
Average Tenure
53.5yo
Average Age
Experienced Management: CUE's management team is seasoned and experienced (6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 7.8yrs | US$3.02m | 0.28% $ 286.6k | |
| Co-Founder and Chairman of Scientific & Clinical Advisory Board | 9.3yrs | no data | no data | |
| Independent Director | 5.9yrs | US$76.31k | 0% $ 0 | |
| Independent Chairman of the Board | 5.8yrs | US$106.27k | 0.058% $ 59.6k | |
| Independent Director | 8.2yrs | US$144.18k | 0.00073% $ 756.4 | |
| Member of Scientific & Clinical Advisory Board | no data | no data | no data | |
| Member of Scientific & Clinical Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 1.3yrs | no data | no data | |
| Clinical Advisor | 1.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.3yrs | no data | no data | |
| Member of Scientific & Clinical Advisory Board | 7.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.3yrs | no data | no data |
5.9yrs
Average Tenure
66.5yo
Average Age
Experienced Board: CUE's board of directors are considered experienced (5.9 years average tenure).